Results 31 to 40 of about 45,831 (210)

Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway

Cells, 2020
Research on repurposing the old alcohol-aversion drug disulfiram (DSF) for cancer treatment has identified inhibition of NPL4, an adaptor of the p97/VCP segregase essential for turnover of proteins involved in multiple pathways, as an unsuspected cancer ...
Dusana Majera, Zdenek Skrott, Katarina Chroma, Joanna Maria Merchut-Maya, Martin Mistrik, Jiri Bartek   +5 more
doaj   +1 more source

The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer

npj Precision Oncology, 2022
Carriers of germline BRCA2 pathogenic sequence variants have elevated aggressive prostate cancer risk and are candidates for precision oncology treatments.
Kevin H. Kensler, Shakuntala Baichoo, Shailja Pathania, Timothy R. Rebbeck   +3 more
doaj   +1 more source

Do we know properly young age breast cancer patients: a double centre study

Journal of Biochemical and Clinical Genetics, 2021
Background: According to American Cancer Society, an estimated 268,600 new cases of invasive breast cancer was diagnosed among women, and nearly 50,000 women were under age 50 years.
Hale Onder Yilmaz, Halil Tadkaynatan, Mustafa Gokoglu, Orkun Yilmaz, Gokmen Aktas   +4 more
doaj   +1 more source

Bayesian assessment of the prevalence of BRCA-associated breast cancer in Moscow

Alʹmanah Kliničeskoj Mediciny, 2020
Rationale: For many years, breast cancer has been leading in the cancer structure in women, accounting for 21% from the total number of newly diagnosed cases of malignancies in Russia. The literature on the prevalence of the BRCA-associated breast cancer
A. V. Viskovatykh
doaj   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden. [PDF]

IJU Case Rep
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Yokota K, Kosaka T, Daimon T, Fujiwara S, Nakamura K, Nishihara H, Oya M.   +6 more
europepmc   +2 more sources

?????? ??????????????: ???????????????? ?????????????? ?????????????? ???? ???????????????? ???????????????? ???????????????????? ?????????????? ?? ?????????? BRCA1 ???? BRCA2 [PDF]

, 2019
?? ???????????? ???????????????????????????? ???????? ???????????????????? ?? ???????????????????? ?????????????? ???????????????????? ???????????????? ???????? ?????????????? (????) ???? ??????????????, ???? ?????????????????????? ?? ?????????????????? ?? ??????????-???????????????????? ???????????????????? ?????????? BRCA1/2, ?? ???? ?????????????????
openaire   +3 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER

Сибирский онкологический журнал, 2017
Germ-line mutations in BRCA1 and BRCA2 genes are the most established risk factors for hereditary breast and ovarian cancers. The purpose of the study was to analyze BRCA1/2 testing in ovarian cancer patients. Materials and methods.
K. B. Kotiv, T. V. Gorodnova, A. O. Ivantsov, A. G. Iyevleva, S. N. Aleksakhina, G. M. Manichas, A. S. Lisyanskaya, R. P. Salomatov, M. S. Shushaniia, M. V. Borodenko, L. D. Roman, G. I. Mikhailiuk, O. N. Mikheeva, T. G. Grigorieva, I. V. Berlev, E. N. Imyanitov, A. P. Sokolenko   +16 more
doaj   +1 more source

Histopathological characterization of carcinoma breast with BRCA1/2 sequence variation in a Tertiary Care Center in Kerala, South India

Biomedical and Biotechnology Research Journal, 2022
Background: Hereditary breast cancers constitute around 5%–10% of all breast cancers. The most commonly mutated genes in hereditary breast and ovarian cancer syndrome are the BRCA1 and BRCA2 genes.
Reeba Mary Issac, Prema Saldanha, Jessy Mangalathu Mathai, Jency Mathews, Rebecca Mathews, Bindu Kumari, Tiju Chacko   +6 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source